评估孟加拉国基础免疫中灭活脊髓灰质炎疫苗与二价口服脊髓灰质炎疫苗序贯接种方案的系统体液免疫和肠道黏膜免疫:一项开放标签、随机对照试验
在孟加拉国达卡开展开放标签随机对照非劣效性试验,456名6周龄健康婴儿随机分配至A组(6周IPV+bOPV,10、14周bOPV)或B组(6周IPV,10、14周bOPV)。18周时两组血清型1、2、3体液免疫应答无显著差异;B组bOPV攻击后1周病毒排出非劣效于A组。
要点
- 18周时A组与B组血清型1、2、3体液免疫应答均无显著差异。
- B组bOPV攻击后1周病毒排出非劣效于A组(1型差异-3%,3型差异-3%)。
- 26例不良事件(含7例严重不良事件)中无一归因于研究疫苗。
核心结论
- IPV-bOPV-bOPV序贯方案诱导的对所有脊髓灰质炎病毒型的系统体液免疫以及对1型和3型的肠道黏膜免疫与IPV+bOPV-bOPV-bOPV共同接种方案相当。
研究设计与样本
- 开放标签、随机对照、非劣效性、不平等试验,在孟加拉国达卡开展,456名6周龄健康婴儿于2015年5月至8月入组并随机分配。
主要发现
- 改良意向性分析纳入428名(94%)受试者(A组211名,B组217名)。
- 18周时A组与B组体液免疫应答:1型98% vs 96%(p=0.42),2型37% vs 39%(p=0.77),3型97% vs 93%(p=0.07)。
- B组bOPV攻击后1周病毒排出非劣效于A组:1型差异-3%(90%CI:-6至0.4%),3型差异-3%(90%CI:-6至-0.2%)。
- 25名受试者报告26例不良事件,包括7例严重不良事件和1例死亡,均未归因于研究疫苗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2012, the Strategic Advisory Group of Experts on Immunization (SAGE) recommended introduction of at least one inactivated poliovirus vaccine (IPV) dose in essential immunization programs. We evaluated systemic humoral and intestinal mucosal immunity of a sequential IPV-bivalent oral poliovirus vaccine (bOPV) schedule compared with a co-administration IPV + bOPV schedule in an open-label, randomized, controlled, non-inferiority, inequality trial in Dhaka, Bangladesh. Healthy infants aged 6 weeks were randomized to either: (A) IPV and bOPV at 6 and bOPV at 10 and 14 weeks (IPV + bOPV-bOPV-bOPV); or (B) IPV at 6 and bOPV at 10 and 14 weeks (IPV-bOPV-bOPV). Of 456 participants enrolled and randomly assigned during May-August 2015, 428 (94%) were included in the modified intention-to-treat analysis (arm A: 211, arm B: 217). Humoral immune responses did not differ at 18 weeks between study arms: type 1 (98% versus 96%; p = 0.42), type 2 (37% versus 39%; p = 0.77), and type 3 (97% versus 93%; p = 0.07). Virus shedding one week after the bOPV challenge dose in arm B was non-inferior to arm A (type 1 difference = -3% [90% confidence interval: -6 - 0.4%]; type 3 difference: -3% [-6 to -0.2%]). Twenty-six adverse events including seven serious adverse events were reported among 25 participants including one death; none were attributed to study vaccines. An IPV-bOPV-bOPV sequential schedule induced comparable systemic humoral immunity to all poliovirus types and types 1 and 3 intestinal mucosal immunity as an IPV + bOPV-bOPV-bOPV co-administration schedule.
引用
- Snider CJ, Zaman K, Estivariz CF, et al. Assessing the mucosal intestinal and systemic humoral immunity of sequential schedules of inactivated poliovirus vaccine and bivalent oral poliovirus vaccine for essential immunization in Bangladesh: An open-label, randomized controlled trial. Vaccine. 2024. PMID: 39146859. doi:10.1016/j.vaccine.2024.126216
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。